🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 29 of 116

  1. AB-101

    Artiva Biotherapeutics

    Non Hodgkin Lymphoma

    phase 2 small molecule completed

    1 trial

  2. AB-201

    Artiva Biotherapeutics

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  3. AB680

    Arcus Biosciences

    Metastatic Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  4. AB8939, Vidaza 25 mg/ml powder for suspension for injection, Venclyxto 100 mg film-coated tablets

    AB Science

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  5. ABC294640

    RedHill Biopharma

    Cholangiocarcinoma

    phase 2 small molecule completed

    1 trial

  6. ABC294640

    Apogee Therapeutics

    Carcinoma, Hepatocellular

    phase 2 small molecule terminated

    1 trial

  7. ABC294640

    Apogee Therapeutics

    Diffuse Large B Cell Lymphoma

    phase 2 small molecule terminated

    1 trial

  8. ABEMACICLIB , RO7197597

    Fondazione Telethon ETS

    ER-positive, HER2-negative Early breast cancer

    phase 2 small molecule active

    1 trial

  9. ABIRATERONE, DAROLUTAMIDE, DZR123, -, -, ABIRATERONE, DZR123, DAROLUTAMIDE

    Novartis Pharmaceuticals

    Metastatic hormone-sensitive prostate cancer

    phase 2 small molecule active

    1 trial

  10. ACETYLCYSTEINE , DEXAMETHASONE , DIPHENHYDRAMINE , GLUCOSE

    Inhibrx Biosciences

    Unresectable or metastatic conventional chondrosarcoma

    phase 2 small molecule active

    1 trial

  11. ACR-368

    Acrivon Therapeutics

    Endometrial Adenocarcinoma

    phase 2 small molecule active

    1 trial

  12. ACTIQ®

    Teva Pharma GmbH

    Cancer

    phase 2 small molecule completed

    1 trial

  13. ADCETRIS 50 mg powder for concentrate for solution for infusion

    Takeda

    Hodgkin lymphoma (HL) - Hodgkin lymphoma (HL), a neoplasm of lymphoid tissue which is histopathologically defined by the presence of malignant Hodgkin Reed-Sternberg (HRS) cells in a background of inflammatory cells. The proposed pediatric study has been designed to evaluate brentuximab vedotin as a component of a multiagent frontline chemotherapy regimen in patients with advanced stage, newly diagnosed HL, here defined as Stage III and Stage IV and a ≥50 Lansky Play-Performance or Karnofsky Performance Status.

    phase 2 small molecule active

    1 trial

  14. ADCETRIS 50 mg powder for concentrate for solution for infusion, DACARBAZINE , DOXORUBICIN , DEXAMETHASONE , VINBLASTINE , CYCLOPHOSPHAMIDE , ETOPOSIDE

    Ningbo Cancer Hospital

    Advanced stage Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  15. ADCT-301

    ADC Therapeutics SA

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule terminated

    1 trial

  16. ADENOVIRUS/PSA VACCINE

    United Therapeutics Europe Ltd

    Hormone Refractory Prostate Cancer

    phase 2 mab completed

    1 trial

  17. ADSTILADRIN

    Ferring Pharmaceuticals

    Low-grade upper track urothelial carcinoma (LG-UTUC)

    phase 2 small molecule active

    1 trial

  18. AFM13

    Artiva Biotherapeutics

    Relapsed or Refractory Hodgkin Lymphoma

    phase 2 small molecule terminated

    1 trial

  19. AG-013736

    Pfizer

    Thyroid Neoplasms

    phase 2 small molecule completed

    1 trial

  20. AG-120

    Agios Netherlands B.V.

    Chondrosarcoma

    phase 2 small molecule active

    1 trial

  21. AG-120/S95031 250mg film-coated tablet, IMFINZI 50 mg/mL concentrate for solution for infusion., Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    The George Institute

    Locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation

    phase 2 small molecule active

    1 trial

  22. AK104

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Resectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  23. AK104

    Akeso

    Advanced Malignant Tumors

    phase 2 small molecule active

    1 trial

  24. AK104, nab-paclitaxel, carboplatin

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  25. AK105 and anlotinib

    The First People's Hospital of Lianyungang

    Cervical Cancer

    phase 2 small molecule active

    1 trial

  26. AK112

    Summit Therapeutics

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  27. AK112, Cadonilimab, nab-paclitaxel, gemcitabine

    Akeso

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  28. AK117

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  29. AL8326

    Lacuna Pharma Pty Ltd

    Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage., Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage.

    phase 2 small molecule active

    1 trial

  30. AL8326

    Lacuna Pharma Pty Ltd

    - Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment., - Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment.

    phase 2 small molecule active

    1 trial

  31. ALDESLEUKIN , TIL cells

    Disc Medicine

    Ovarian carcinoma

    phase 2 small molecule active

    1 trial

  32. ALDESLEUKIN , Tumor Intiltrating Lymphocytes (TIL) – VHIO, FLUDARABINE , CYCLOPHOSPHAMIDE

    The George Institute

    Germ Cell Tumors refractory to salvage chemotherapy

    phase 2 small molecule active

    1 trial

  33. ALECTINIB

    Hoffmann-La Roche

    ALK fusion-positive extracranial solid or primary CNS tumors who have progressed following prior treatment or who have no satisfactory treatment available

    phase 2 small molecule active

    1 trial

  34. ALEXAN, 50 MG/ML, ROZTWÓR DO INFUZJI, Liposomal Annamycin

    Moleculin Biotech

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  35. ALG.APV-527

    Aptevo Therapeutics

    Solid Tumor

    phase 2 small molecule active

    1 trial

  36. ALIMTA 500 mg powder for concentrate for solution for infusion, ALIMTA 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PDC*lung01, PDC*lung01

    Lacuna Pharma Pty Ltd

    Non-small-cell lung cancer

    phase 2 small molecule active

    1 trial

  37. ALLO-501A

    Allogene Therapeutics

    Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

    phase 2 gene therapy active

    1 trial

  38. ALLO-647

    Allogene Therapeutics

    Relapsed/Refractory Large B Cell Lymphoma

    phase 2 mab terminated

    1 trial

  39. ALPELISIB, FULVESTRANT, ALPELISIB, LETROZOLE, LEUPRORELIN ACETATE, GOSERELIN

    Novartis Pharmaceuticals

    Adult patients with PIK3CA mutant, HR-positive, HER2-negative advanced breast cancer

    phase 2 small molecule active

    1 trial

  40. ALPELISIB, RIBOCICLIB, LETROZOLE, LEE011, ALPELISIB, LEE011

    Novartis Pharmaceuticals

    Advanced HR+ breast cancer

    phase 2 small molecule active

    1 trial

  41. AMG 193

    Amgen

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  42. AMG 193, AMG 193, AMG 193

    Amgen

    Advanced MTAP-null solid tumors

    phase 2 small molecule active

    1 trial

  43. AMG 193, IDE397, AMG 193, IDE397, AMG 193

    Amgen

    In Part 1, subjects with advanced MTAP-null solid tumors and, in Part 2, subjects with advanced MTAP-null Non Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  44. AMG 706

    Takeda

    Advanced Gastrointestinal Stromal Tumor

    phase 2 small molecule completed

    1 trial

  45. APR-246

    Aprea Therapeutics

    Acute Myeloid Leukemia or Myelodysplastic Syndromes

    phase 2 small molecule completed

    1 trial

  46. APR-246

    Aprea Therapeutics

    Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

    phase 2 small molecule completed

    1 trial

  47. APR-246

    Aprea Therapeutics

    Melanoma

    phase 2 small molecule terminated

    1 trial

  48. APR-246

    Aprea Therapeutics

    High-grade Serous Ovarian Cancer

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.